Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line

SACHIKO OGASAWARA1*, MASAMICHI NAKAYAMA1*, JUN AKIBA2, HIRONORI KUSANO1 and HIROHISA YANO3

1Department of Pathology, Kurume University School of Medicine; 2Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan

Received September 26, 2016; Accepted January 6, 2017

DOI: 10.3892/ol.2017.6451

Abstract. Patients with hepatocellular carcinoma (HCC) who respond to sorafenib have been reported to exhibit an increase in the level of des-γ-carboxyprothrombin (DCP) in the blood, subsequent to the initiation of sorafenib treatment. In the present study, the levels of secretion of DCP and DCP with more γ-carboxyglutamic residues (NX-DCP) and the effects of hypoxic conditions were examined in 13 liver cancer cell lines, and the presence of vitamin K and sorafenib, in the KYN-2 cell line, which resulted in confirmed DCP and NX-DCP secretion. DCP, NX-DCP and prothrombin secretion were confirmed in 2/13 cell lines, KYN-2 and KIM-1. The level of secretions increased under hypoxic conditions. The addition of vitamin K suppressed cell proliferation, and DCP expression decreased to below detectable levels, however the level of prothrombin expression increased. Sorafenib treatment increased the level of apoptosis and suppressed cell proliferation, and decreased DCP and NX-DCP. In contrast, levels of prothrombin and vascular endothelial growth factor (VEGF) expression exhibited a slight increase. When the same experiment was conducted under hypoxic conditions, DCP secretion significantly decreased in the presence of sorafenib. The level of DCP secretion increased by several fold in the sorafenib-treated and non-treated cells compared with the normoxic conditions. Prothrombin and VEGF values with normoxic conditions remained almost similar with hypoxic conditions. Under hypoxic conditions, NX-DCP significantly decreased below the control values for the first 48 h subsequent to sorafenib treatment, but significantly increased at 72 h. In vivo experiments demonstrated that sorafenib inhibited angiogenesis and tumor proliferation, but the levels of DCP and NX-DCP did not differ significantly from the controls. These findings indicate that the suppression of neovascularization by sorafenib promotes blood vessel ischemia, producing hypoxic conditions whereby vitamin K uptake and utilization efficiency is reduced.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common types of cancer and the second leading cause of malignant-neoplasm-associated mortality, worldwide (1). However, the molecular targeted therapy, sorafenib, has exhibited promising results in the treatment of patients with advanced HCC (2). Sorafenib is a small molecule that functions as an oral multikinase inhibitor and is also approved for the treatment of advanced renal cell carcinoma (3). Sorafenib exhibits direct antiproliferative effects on tumor cells due to the blockade of numerous intracellular serine/threonine kinases (e.g., C-Raf and B-Raf), and indirect effects due to the blockade of receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor-β (PDGFR-β) on endothelial cells followed by the inhibition of angiogenesis (1,4,5). Des-γ-carboxyprothrombin (DCP), also known as protein induced by vitamin K absence or antagonist-II (PIVKA-II), is an abnormal prothrombin with more γ-carboxyglutamic (Gla) residues and was termed NX-DCP. A number of previous studies reported that serum NX-DCP was also useful for the detection of HCC (6,9). We previously revealed that patients with serum NX-DCP-positive HCC exhibited significantly larger tumors, more frequent portal vein invasion and a poorer prognosis (10). The evaluation of α-fetoprotein (AFP) level is already used for routine surveillance and noninvasive diagnosis of HCC, and the prediction of prognosis and monitoring of recurrence subsequent to treatment (11,12). As the DCP level is not always correlated with the AFP level, the recommendations in previous studies include combined testing of
DCP and *Lens culinaris* agglutinin-reactive fraction of AFP has been established (13,14).

Sorafenib is widely used for patients with advanced HCC. However, at present, there are no clinical parameters to predict sorafenib efficacy. DCP levels were reported to be increased in patients treated with sorafenib (15-17), and the elevation of DCP may indicate a high therapeutic effect of sorafenib (16,17).

Although the precise mechanism remains unknown, the ischemic and/or hypoxic conditions of HCC may be associated with the elevation of DCP subsequent to sorafenib treatment. In the present study, the mechanism of DCP level elevation in hypoxic conditions and sorafenib treatment was investigated using the HCC KYN-2 cell line, which produces DCP.

Materials and methods

**Cell lines and cell culture.** The present study used 11 HCC cell lines KIM-1, KYN-1, KYN-2, KYN-3, HAK-1A, HAK-1B, HAK-2, HAK-3, HAK-4, HAK-5 and HAK-6, and 2 combined hepatocellular-cholangiocarcinoma (CHC) cell lines, KMCH-1 and KMCH-2. These cell lines were originally established in the Department of Pathology (Kurume University School of Medicine, Kurume, Japan), and each cell line retains the morphological and functional features of the original tumor as described elsewhere (18-26). The cells were grown in Dulbecco's modified Eagle's medium (Nissui, Tokyo, Japan) supplemented with 2.5% heat-inactivated (56°C, 30 min) fetal bovine serum (FBS; Bioserum, Victoria, Australia), 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 12 mmol/l sodium bicarbonate, in a humidified atmosphere of 5% CO₂ at 37°C.

**Measurement of DCP, NX-DCP and prothrombin levels.** The cultured cells were seeded on 6-well plates (Falcon, BD Biosciences Labware, Tokyo, Japan) at a density of 3-10x10³ cells/well, and cells on the plates were cultured in normoxic or hypoxic, 1% O₂, conditions for 3 days. The prothrombin, DCP and NX-DCP levels in the supernatant (centrifuged for 10 min, 12,000 x g, 4°C) and cell lysate were determined using an ELISA kit (EIDIA Co., Ltd., Tokyo, Japan) for prothrombin and an electro-chemiluminescence immunoassay (ECLIA) kit (EIDIA Co., Ltd.) for DCP and NX-DCP, according to the protocol of the manufacturer. The polyclonal antibody for prothrombin was sourced from the ELISA kit, the monoclonal antibody for DCP (MU-3) and monoclonal antibodies for NX-DCP (P-11 and P-16) were sourced from the ECLIA kit.

**Effects of vitamin K on the secretion of DCP, NX-DCP and prothrombin.** KYN-2 cells were seeded on 10 cm² dishes (Falcon, BD Biosciences Labware) at a density of 1.3x10⁵ cells/well. The media were replaced the subsequent day with medium alone or medium containing 100 nM vitamin K (Sigma-Aldrich; Merck Millipore; Darmstadt, Germany) and the cells were cultured in normoxic or hypoxic condition for 72 h. The cell number was then determined and the supernatant was collected (centrifuged for 10 min, 12,000 x g, 4°C) and used for DCP, NX-DCP and prothrombin measurements by ECLIA and ELISA.

**Effect of sorafenib on proliferation and secretion of DCP, NX-DCP, prothrombin and VEGF.** A total of 5x10⁶ cells per well KYN-2 cells were seeded on 6-well plates. The medium was replaced the next day with medium alone or medium containing 1.25 µM sorafenib (Cell Signaling Technology, Danvers, MA) and the cells were cultured in normoxic or hypoxic condition for 24, 48, or 72 h. Then the cell number was determined and the supernatant was collected and used for DCP, NX-DCP, prothrombin and vascular endothelial growth factor (VEGF) measurements by ECLIA and ELISA. The supernatant was also obtained from cells cultured with sorafenib (0.313, 0.625 or 1.25 µM) for 72 h and used for the evaluation performed by ECLIA and ELISA.

**Effects of sorafenib on tumor proliferation and serum DCP and NX-DCP levels in nude mice.** A total of 1x10⁵ cells/100 µl cultured KYN-2 cells were subcutaneously injected into the backs of 4-week-old female BALB/c nude mice. Following two weeks, the mice were divided into 3 groups of 12 in order to equalize the mean diameter of tumors in each group. Each group was assigned to 1 of the 3 treatment groups: Control; 300 µg/mouse/day sorafenib; 600 µg/mouse/day sorafenib. The 300 µg dose of sorafenib in proportion to the average body weight of a mouse, 20 g, was 15 mg/kg, which is comparable to a clinical dose of 800 mg total/day. The sorafenib was diluted with 12.5% Cremophor EL (Sigma-Aldrich; Merck Millipore) 12.5% ethanol/75% water for oral dosing in mice, and was administered by tube feeding once a day. In the control group, 0.2 ml Cremophor EL/ethanol/water (12.5/12.5/75) alone was administered by tube feeding once a day. Tumor size was measured in two directions using calipers, and tumor volume (mm³) was estimated by using the equation: Length x (width)^² x 0.5. This measurement was performed every 2 or 3 days. On day 4, 9 or 14, subsequent to drawing blood for measuring the serum DCP and NX-DCP level, 4 mice in each group were sacrificed by cervical dislocation and the tumors were resected. The tumor weight was measured.

**Immunohistochemical analysis.** The resected tumors were fixed in formalin and prepared into paraffin sections, and underwent hematoxylin and eosin staining and immunohistochemistry. Immunohistochemical staining with monoclonal rat anti-mouse cluster of differentiation (CD34) (cat. no. ab8185; dilution, 1:50; Abcam, Cambridge, UK) was performed using the standard avidin-biotin-peroxidase complex method and 3,3'-diaminobenzidine solution was used for color development. The microvessel density (MVD) was evaluated within the tumor. To quantify MVD, the slides stained with CD34 underwent hematoxylin and eosin staining and immunohistochemical analysis. The slides stained with CD34 and the images were captured using a light microscope. A total of 5 areas with high MVD were selected at a high-power field, magnification, x200, and the MVD of these areas in each specimen was measured using the WinROOF software package (version 6.1; Mitani Corporation, Fukui, Japan).

**Statistical analysis.** Data are expressed as the mean ± standard deviation. Comparisons between groups were performed using un-paired Student's t-test and two-factor factorial analysis of variance. P<0.05 was considered to indicate a statistically significant difference.
**Results**

**Measurement of DCP, NX-DCP and prothrombin.** The levels of DCP secretion in the supernatant of KYN-2 cells under normoxic conditions per µg protein was 11.2 mAU/µg protein, and the expression in the cell lysate was 165.4 mAU/µg protein. Under hypoxic conditions, the DCP expression levels were 66.7 mAU/µg protein in the supernatant, and 80.9 mAU/µg protein in the cell lysate. In the KIM-1 cells, the level of DCP secretion in the supernatant cultured under normoxic conditions was 0.8 mAU/µg protein, and the expression in the cell lysate was 126.7 mAU/µg protein. In hypoxic conditions, the levels of DCP expression were 19.1 mAU/µg protein in the supernatant, and 872.4 mAU/µg protein in the cell lysate. The levels of NX-DCP secretion in the supernatant of the KYN-2 cells was 0.3 mAU/µg protein under normoxic conditions, and 0.9 mAU/µg protein under hypoxic condition. In the KIM-1 cells, the levels of NX-DCP secretion in the supernatant were 0.2 mAU/µg protein under normoxic conditions, and 0.7 mAU/µg protein under hypoxic condition. The levels of prothrombin secretion under normoxic conditions were 0.6 mAU/µg protein in KYN-2 cells, and 0.6 mAU/µg protein in the KIM-1 cells. Under hypoxic conditions, the levels of prothrombin expression were 0.9 mAU/µg protein, and 0.9 mAU/µg protein for KYN-2 and KIM-1, respectively. The expression levels of DCP, NX-DCP and prothrombin in all of the other 11 cell lines were less than 0.1 mAU/µg protein (data not shown).

**Effects of vitamin K on secretion of DCP, NX-DCP and prothrombin.** The addition of vitamin K to the culture medium suppressed cell proliferation in the KYN-2 cells under normoxic or hypoxic conditions, as demonstrated in Fig. 1A. The level of secretion of DCP under normoxic condition without the addition of vitamin K was 118.0±2.2 mAU/ml/10⁴ cells, whereas levels of DCP increased significantly to 428.2±14.2 mAU/ml/10⁴ cells under hypoxic condition (P<0.001). However, when vitamin K was added to the cell cultures, the levels DCP secretion decreased below 0.5 mAU/ml/10⁴ cells in normoxic and hypoxic condition, as illustrated in Fig. 1B. NX-DCP expression in normoxic and hypoxic conditions was <1.0 mAU/ml/10⁴ cells. NX-DCP expression was not detected with the addition of vitamin K, as demonstrated in Fig. 1C. The levels of prothrombin secretion were 1.2±0.1 mAU/ml/10⁴ cells under normoxic conditions without vitamin K, and increased to 2.6±0.1 mAU/ml/10⁴ cells under hypoxic conditions (P<0.001). Subsequent to the addition of vitamin K, the prothrombin levels were 2.4±0.1 mAU/ml/10⁴ cells under normoxic conditions, but increased to 7.1±0.7 mAU/ml/10⁴ cells in hypoxic conditions (P<0.001), as illustrated in Fig. 1D.

**Effect of sorafenib on proliferation and secretion of DCP, NX-DCP, prothrombin and VEGF.** The cells cultured with 1.25 µM sorafenib decreased in number to 25% of the control group on day 3 (P<0.001), as demonstrated in Fig. 2A. Sorafenib inhibited the levels of DCP secretion by the HCC cells: The levels of DCP in the culture medium of the control cells at 24, 48 and 72 h were 0.21±0.04, 8.4±0.72 and 48.2±14.9 mAU/ml/10⁴ cells, respectively, and in cells cultured with 1.25 µM sorafenib the levels of DCP secretion at 24, 48 and 72 h were 0.16±0.03, 0.29±0.10 and 0.66±0.01 mAU/ml/10⁴ cells, respectively (P<0.001), as illustrated in Fig. 2B. Levels of NX-DCP expression demonstrated a similar trend to DCP. The expression of NX-DCP was generally low, as the highest level was 0.35±0.09 mAU/ml/10⁴ cells at 72 h in the non-sorafenib cell culture, as demonstrated in Fig. 2C. Prothrombin and VEGF secretion at 24, 48, and 72 h were all elevated in the sorafenib-treated cell cultures. These expression levels peaked at 48 h and increased >2-fold compared with the non-treated cells (P<0.001), as illustrated in Fig. 2D and E.

The same experiments were performed under hypoxic conditions. The levels of cell proliferation decreased subsequent to sorafenib treatment, but the difference was less compared with normoxic conditions, as demonstrated in Fig. 2F. DCP expression was higher in the sorafenib-treated and non-treated cells compared with the cells under normoxic conditions. The level of DCP in the sorafenib-treated cells was significantly lower compared with the control group and the cells under normoxic conditions (P<0.001), as illustrated.
OGASAWARA et al: THE EFFECTS OF HYPOXIA AND SORAFENIB PRODUCTION ON DCP PRODUCTION

**Figure 2.** Effect of sorafenib on the proliferation and secretion of DCP, prothrombin, NX-DCP and VEGF. Upper row (A-E), normoxic conditions; lower row (F-J), hypoxic conditions. (A and F) The number of KYN-2 cells cultured with or without 1.25 µM sorafenib for 24, 48, or 72 h. The levels of (B and G) DCP; (C and H) NX-DCP; (D and I) prothrombin; and (E and J) VEGF secreted by KYN-2 cells cultured with medium alone or medium with 1.25 µM sorafenib for 24, 48, or 72 h. Data are present as the mean ± standard deviation from three independent experiments. †P<0.01 and *P<0.001 medium alone vs. medium with sorafenib. DCP, des-γ-carboxyprothrombin; NX-DCP, des-γ-carboxyprothrombin with more γ-carboxyglutamic residues; VEGF, vascular endothelial growth factor; ■/black bar, cells cultured with 1.25 µM sorafenib; •/gray bar, cells cultured without 1.25 µM sorafenib.

Subsequent to culturing the cells for 72 h with the addition of sorafenib at a range of concentrations, or without sorafenib, cell proliferation was more significantly suppressed under hypoxic conditions compared with under normoxic conditions. Under these two conditions, sorafenib treatment significantly suppressed cell proliferation (P<0.001), as demonstrated in Fig. 3A. The level of DCP secretion under normoxic conditions decreased subsequent to sorafenib treatment in a dose-dependent manner, but this effect was enhanced in hypoxic conditions (P<0.001), as illustrated in Fig. 3B. NX-DCP expression was low compared with DCP, and

**Figure 3.** Dose-dependent effect of 0.313, 0.625 or 1.25 µM sorafenib on the levels of proliferation and secretion of DCP, prothrombin, NX-DCP and VEGF. (A) KYN-2 cells were cultured with medium alone or medium with 0.313, 0.625, or 1.25 µM sorafenib in normoxic or hypoxic conditions for 72 h. The (A) cell number and levels of (B) DCP, (C) NX-DCP, (D) prothrombin and (E) VEGF secreted by KYN-2 cells cultured with or without sorafenib in normoxic or hypoxia conditions for 72 h. †P<0.01 and *P<0.001 vs. normoxic condition. •/gray bar, normoxic conditions; ■/black bar, hypoxic conditions; DCP, des-γ-carboxyprothrombin; NX-DCP, des-γ-carboxyprothrombin with more γ-carboxyglutamic residues; VEGF, vascular endothelial growth factor.

in Fig. 2G. NX-DCP expression in sorafenib-treated cells was higher compared with the control at 72 h, as demonstrated in Fig. 2H. The levels of secretion of prothrombin and VEGF under hypoxic conditions were almost the same as under normoxic conditions, as illustrated in Fig. 2I and J. VEGF secretion increased 1.5- to 2-fold compared with non-treated cells under normoxic conditions.

Subsequent to culturing the cells for 72 h with the addition of sorafenib at a range of concentrations, or without sorafenib,
tended to decrease subsequent to sorafenib treatment under normoxic conditions. However, NX-DCP levels exhibited an increase under hypoxic conditions (P<0.001), as demonstrated in Fig. 3C. The secretion of prothrombin and VEGF was also significantly higher under hypoxic conditions in cells treated with high concentrations of sorafenib compared with normoxic conditions (P<0.001), as illustrated in Fig. 3D and E.

**Effects of sorafenib on tumor proliferation and serum DCP and NX-DCP levels in nude mice.** The growth of the tumor (tumor volume) was suppressed in sorafenib-treated mice from day 7 compared with the control, and this difference was significant at day 13 (P<0.05), as demonstrated in Fig. 4A. Tumor weight also decreased significantly at day 14 in sorafenib-treated mice compared with the control (P<0.05), as illustrated in Fig. 4B. The tumor volume and weight decreased ~50% of the control level subsequent to sorafenib treatment, however no difference was observed between the two dose levels, 300 µg/mouse/day or 600 µg/mouse/day, used in the present study. The levels of DCP expression by tumor weight was 622.2±66.4 mAU/ml/g in the control, 430.7±77.7 mAU/ml/g in the sorafenib 300 µg/mouse/day and 763.1±78.4 mAU/ml/g in the sorafenib 600 µg/mouse/day group, as illustrated in Fig. 5A. The levels of NX-DCP expression per unit tumor weight was 11.2±3.3 mAU/ml/g in the control, 15.3±5.8 mAU/ml/g in the sorafenib 300 µg/mouse/day group and 31.1±9.5 mAU/ml/g in the sorafenib 600 µg/mouse/day group, as demonstrated in Fig. 5B. There were no significant differences observed between the levels of expression of DCP or NX-DCP between the sorafenib and control groups.

**Immunohistochemical analysis.** MVD was significantly reduced to 68.4% of the control level in the sorafenib 300 µg/mouse/day group, and 59.4% of the control level in the sorafenib 600 µg/mouse/day group (P<0.001). No significant difference in other parameters, such as tumor volume and
Discussion

The 10 glutamic acid (Glu) residues of human prothrombin at the N-terminus are typically converted by carboxylase to a Gla domain. DCP is an abnormal prothrombin as all or part of the Gla domain remains as Glu residues. NX-DCP, which is induced in conditions of vitamin K deficiency, is a protein with a smaller number of Glu residues.

In the present study, the levels of DCP, NX-DCP and prothrombin expression in 13 different cell lines were examined. It was revealed that the expression levels were low in all cell lines except KIM-1 and KYN-2. Comparing the expression levels of DCP, NX-DCP and prothrombin under normoxic or hypoxic conditions, the levels increased under hypoxic conditions in all categories except DCP in the KYN-2 cell lysate. NX-DCP and prothrombin were expressed under hypoxic conditions, but the levels were low compared with levels of DCP. The production of DCP in HCC is hypothesized to be associated with a reduction in the activity of vitamin K dependent γ-carboxylase (27,28), excessive production of prothrombin precursors (29,30) and to effects associated with vitamin K concentration. In the present study, cell proliferation and DCP expression were suppressed under normoxic and hypoxic conditions in KYN-2 cells treated with vitamin K. This suggests that the addition of vitamin K restored the metabolic pathways to near normal status in the KYN-2 cells where the increased expression of prothrombin lowered the uptake or reduced the activity of vitamin K. In studies using cell lines, vitamin K treatment was demonstrated to suppress DCP expression, whilst increasing the expression of prothrombin and carboxylase mRNA (31,32). These results suggest that DCP production in HCC may be caused by a reduction in vitamin K concentration in the microenvironment of the cancer cells. Conversely, vitamin K derivatives are not reduced in patients with HCC, and one study reported that vitamin K administration reduced DCP levels (33). However, whilst vitamin K administration reduced DCP to normal levels in patients exhibiting a high serum level of vitamin K derivatives, DCP remained abnormal in patients exhibiting low serum levels of vitamin K derivatives. These data indicate that high levels of DCP are not caused by lowered levels of vitamin K, but by a reduced utilization efficiency caused by a defect in vitamin K metabolism.

A transitory increase in DCP has been reported in certain patients with HCC subsequent to sorafenib treatment (34). Additionally, progression-free survival in those patients who exhibited an increase in DCP expression levels was longer compared with the patients who exhibited no increase in DCP (17,35). The elevation of DCP subsequent to sorafenib treatment may be a prognostic marker, and this elevation may be caused by tumor cell ischemia. Sorafenib at concentrations of 0.3125-20 µM suppressed cell proliferation in a dose-dependent manner in all 13 cell lines used in the present study (data not shown). Similar to the results revealed by Llovet et al (36) and Fernando et al (37), apoptosis was induced in 8 of the cell lines in between 5 to 50% of the cells, however the induction of autocrine cell proliferation by DCP or activation of hepatocyte growth factor receptor was not observed such as the report of Suzuki et al (38) and Gao and Vande Woude (39).

In the in vivo experiment of the present study, tumor volume and weight, and blood vessel density were suppressed in mice receiving 600 µg/mouse/day sorafenib, compared with the control group. The present study hypothesizes that the inhibitory effect of sorafenib on neovascularization is responsible for the suppression of tumor proliferation. Also, NX-DCP secretion per unit weight increased in the sorafenib-treated mice, which may be an additional mechanism of creating a hypoxic environment through the inhibition of neovascularization.

The levels of DCP and NX-DCP secretion were significantly decreased in sorafenib treated cell cultures compared with the non-treated controls, whereas levels of prothrombin and VEGF expression were increased. However, under normoxic conditions levels of NX-DCP expression increased at 72 h subsequent to sorafenib treatment. The DCP values increased under hypoxic conditions compared with normoxic conditions, but decreased significantly in the cells cultured with sorafenib. With regard to the increase in levels of DCP expression under hypoxic conditions, as reported by Murata et al (40), hypoxic conditions induce epithelial to fibroblastoid conversion and epithelial mesenchymal transition, which may inhibit vitamin K uptake and stimulate DCP production. Conversely, levels of NX-DCP secretion exhibited a different trend compared with DCP in the sorafenib-treated cells under hypoxic conditions. At 48 h, sorafenib suppressed NX-DCP secretion, but at 72 h an increase in NX-DCP was observed. In our previous study of resected HCC tissues, NX-DCP originated from non-tumorous cells in the background, whilst expression within the cancerous area was limited (10). With regard to the production of NX-DCP in HCC, it is possible that the direct effects of sorafenib and blood vessel ischemia may be responsible for the increase in levels of serum NX-DCP. However, NX-DCP from non-cancerous hepatocytes may also be present in the sera to varying degrees, so an accurate assessment of this effect may prove difficult.

As a mechanism for the increase in DCP observed in patients with HCC subsequent to sorafenib treatment, the present study suggests that the suppression of neovascularization by sorafenib promotes blood vessel ischemia, producing hypoxic conditions whereby vitamin K uptake and utilization efficiency is reduced. In these circumstances it is likely that the degree of the increase in serum DCP will be determined according to a balance between the direct suppression of DCP by sorafenib and the increase in DCP secretion due to ischemia.

Acknowledgements

The authors would like to thank Ms. Akemi Fujiyoshi for her assistance in the present study.

References

1. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
21. Jpn J Cancer Res: 292, 1988.

Murakami T, Maruiwa M, Fukuda K, Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310: 1427-1431, 1984.

3. Escudier B, Eisen T, Stanley WM, Szczyluk C, Oudard S, Staepler M, Negril S, Chevreau C, Desai AA, Rolland F, et al: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer: global evaluation trial. J Clin Oncol 27: 3312-3318, 2009.

4. Carlon Magno F, Anagnosti S, Guida T, Salvatore G, Troncone G, Wilhelm SM and Santoro M: BAY 43-9006 inhibition of onco- genic RIT mutants. J Natl Cancer Inst 98: 326-334, 2006.

5. Wilhelm SM, Carter C, Tang L, Wilkie D, McAngela A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 5100-5107, 2004.

6. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS and Furie B: Des-gamma-carboxy (abnormal) prothrombin and alpha-fetoprotein in hepatocellular carcinoma. Am J Surg 163: 251-256, 1992.

7. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A and Maeda H: Protein induced by vitamin K absence or antag- nist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 73: 2464-2471, 1994.

8. Sakamoto N: NX-PVKA assay, a conventional but refined prognostic biomarker for hepatocellular carcinoma. J Gastroenterol Hepatol 22: 251-258, 2006.

9. Sumi A, Akiba J, Ogawasara N, Nakayama M, Nomura Y, Yasumoto M, Sanada S, Nakashima O, Abe T and Yano H: Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepa-tocellular carcinoma. PLoS One 10: e0158452, 2015.

10. Kim BK, Ahn SH, Seong JS, Park JY, Kim DY, Kim JK, Lee DY, Lee KH and Han KH: Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 31: 369-376, 2011.

11. Johnson PJ: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5: 145-159, 2001.

12. Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12: 1175-1181, 2006.

13. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A and Malaguarnera M: Serum markers of hepatocellular carcinoma. World J Gastroenterol 25: 532-539, 2011.

14. Nakazawa T, Hidaka H, Shibuya A and Koizumi W: Rapid production in hepatocellular carcinoma. Int J Oncol 36: 161-170, 2010.

15. Sakamoto N: NX-PVKA assay, a conventional but refined prog- nostic marker for hepatocellular carcinoma. J Gastroenterol Hepatol 22: 251-258, 2006.

16. Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hosokawa T, Kato T, Yasui Y, Nakatuka T, et al: Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 81: 251-258, 2011.

17. Des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity. Int J Oncol 15: 669-675, 1999.

18. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A and Maeda H: Protein induced by vitamin K absence or antag- nist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 73: 2464-2471, 1994.

19. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS and Furie B: Des-gamma-carboxy (abnormal) prothrombin and alpha-fetoprotein in hepatocellular carcinoma. Am J Surg 163: 251-256, 1992.

20. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A and Maeda H: Protein induced by vitamin K absence or antag- nist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 73: 2464-2471, 1994.

21. Sakamoto N: NX-PVKA assay, a conventional but refined prog- nostic biomarker for hepatocellular carcinoma. J Gastroenterol Hepatol 22: 251-258, 2006.

22. Sumi A, Akiba J, Ogawasara N, Nakayama M, Nomura Y, Yasumoto M, Sanada S, Nakashima O, Abe T and Yano H: Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepa-tocellular carcinoma. PLoS One 10: e0158452, 2015.

23. Kim BK, Ahn SH, Seong JS, Park JY, Kim DY, Kim JK, Lee DY, Lee KH and Han KH: Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 31: 369-376, 2011.

24. Johnson PJ: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5: 145-159, 2001.

25. Zhou L, Liu J and Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12: 1175-1181, 2006.

26. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A and Malaguarnera M: Serum markers of hepatocellular carcinoma. Dig Dis Sci 55: 2744-2755, 2010.

27. Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hosokawa T, Kato T, Yasui Y, Nakatuka T, et al: Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 81: 251-258, 2011.

28. Nakazawa T, Hidaka H, Shibuya A and Koizumi W: Rapid production in hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib—a report of two cases. Case Rep Oncol 3: 298-303, 2010.

29. Ueshima K, Kudo M, Hashimoto K: Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 4: 357-363, 1987.

30. Sakamoto N, Monden M, Gotoh M, Kobayashi K, Kanai T, Umesita K, Endoh W and Mori T: The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PVKA-II) in patients with hepatocellular carcinoma. Am J Gastroenterol 86: 7042-7049, 1991.

31. Umesita K, Endoh W and Mori T: The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PVKA-II) in patients with hepatocellular carcinoma. Am J Gastroenterol 86: 7042-7049, 1991.

32. Kuzuya T, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, Tamaki S, Kato T, Yasui Y, Tanaka T, Hosokawa T, et al: Significance of PVKA-II in sorafenib therapy for advanced hepatocellular carcinoma. Kanjo 51: 403-404, 2010.

33. Ueshima K and Kudo M: PVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinoma. Kanjo 51: 681-683, 2010.

34. Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matías-Guix X and Dolcet X: The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 46: 836-850, 2010.

35. Fernando J, Sancho P, Fernández-Rodríguez CM, Lledó JL, Caja L, Campbell JS, Fausto N and Fabregat I: Sorafenib sen-sitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physio 227: 1319-1325, 2012.

36. Suzuki M, Shimata R, Fujiwara M, Saito R, Taoka N, Ueda N, Nakashima Y, Koike K, Takaki A and Shiratori Y: Des-gamma- carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Hepatol 56: 1006-1016, 2012.